Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.90 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
60,310.74 -1,865.06 (-3.00%) CMC Crypto 200
1,261.07 -73.85 (-5.53%)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS)
| Previous close | 21.97 |
| Open | 21.99 |
| Bid | 22.04 x 0 |
| Ask | 22.05 x 0 |
| Day's range | 21.91 - 22.23 |
| 52-week range | 20.38 - 32.08 |
| Volume | |
| Avg. volume | 8,841,808 |
| Market cap | 53.566B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 29.39 |
| EPS (TTM) | 0.75 |
| Earnings date | 27 Aug 2024 - 02 Sept 2024 |
| Forward dividend & yield | 0.42 (1.91%) |
| Ex-dividend date | 09 Aug 2023 |
| 1y target est | 29.11 |
PR NewswireFosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger health and cost lives, but it also perpetuates a vicious cycle of inequity. People living in the most vulnerable situations including pregnant women and children under 5 years of age continue to be disproportionately impacted.
- PR Newswire
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
